| 4.46 0.08 (1.83%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.34 | 1-year : | 6.24 |
| Resists | First : | 4.57 | Second : | 5.34 |
| Pivot price | 4.22  |
|||
| Supports | First : | 4.18 | Second : | 3.94 |
| MAs | MA(5) : | 4.32 |
MA(20) : | 4.21 |
| MA(100) : | 3.86  |
MA(250) : | 6.14 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 67.7 |
D(3) : | 61.1 |
| RSI | RSI(14): 60.6 |
|||
| 52-week | High : | 13.6 | Low : | 2.95 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ OMER ] has closed above the upper band by 3.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 67.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 79 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.52 - 4.54 | 4.54 - 4.56 |
| Low: | 4.2 - 4.22 | 4.22 - 4.24 |
| Close: | 4.43 - 4.46 | 4.46 - 4.49 |
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Sat, 20 Sep 2025
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Wed, 20 Aug 2025
Omeros: Deja Vu All Over Again (Rating Downgrade) (NASDAQ:OMER) - Seeking Alpha
Sun, 27 Jul 2025
Omeros Corporation (NASDAQ:OMER): When Will It Breakeven? - 富途牛牛
Fri, 25 Jul 2025
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering - Yahoo Finance
Fri, 25 Jul 2025
Omeros stock rises after $22 million registered direct offering - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 68 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 42.6 (%) |
| Shares Short | 13,140 (K) |
| Shares Short P.Month | 12,780 (K) |
| EPS | -2.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.67 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -119 (M) |
| Levered Free Cash Flow | -71 (M) |
| PE Ratio | -1.89 |
| PEG Ratio | 0 |
| Price to Book value | -1.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|